NEW YORK (360Dx) – Comparing a new assay to a gold standard is a way to assess performance, but what if the comparator test turns out to have variability between labs or experiments? Accelerate Diagnostics reported earlier this month it has had to slightly delay the start of clinical trials for a pneumonia assay in development because the firm has discovered the gold standard culture methods, which are commonly used by microbiology labs, are too highly variable.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.